<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034814</url>
  </required_header>
  <id_info>
    <org_study_id>IXL-201-14-189</org_study_id>
    <nct_id>NCT00034814</nct_id>
  </id_info>
  <brief_title>Multicenter Trial for Adults With Partial Seizures</brief_title>
  <official_title>Efficacy and Safety of Talampanel as Adjunctive Therapy in Patients With Partial Seizures: A Phase II Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <brief_summary>
    <textblock>
      To compare seizure frequency in patients with refactory partial seizures (with or without
      generalization) who are taking Talampanel versus placebo as an add-on therapy to other
      licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in
      this group of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of
      talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in frequency of partial seizures</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in frequency of recognizable seizures as measured by entries in a seizure diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of seizure-free days and percent responders</measure>
    <time_frame>12 weeks</time_frame>
    <description>A responder was defined as a patient with greater than or equal to 50% reduction in seizure frequency compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Enzyme-inducing placebo TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzyme-inducing Talampanel 35 mg TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzyme-inducing TLP 50mg TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-enzyme-inducing placebo TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-enzyme-inducing TLP 25mg TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-enzyme-inducing TLP 35mg TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talampanel</intervention_name>
    <description>Non-enzyme-inducing TLP 35mg TID</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Enzyme-inducing placebo TID</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talampanel</intervention_name>
    <description>Enzyme-inducing Talampanel 35 mg TID</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talampanel</intervention_name>
    <description>Enzyme-inducing TLP 50mg TID</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Non-enzyme-inducing placebo TID</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talampanel</intervention_name>
    <description>Non-enzyme-inducing TLP 25mg TID</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must weigh greater than or equal to 40kg

          -  Patients must have diagnosis of partial seizures

          -  At least 3 observable partial seizures a month

          -  Are currently being treated with 1 and no more than 2 marketed Anti-epileptic Drugs.

        Exclusion:

          -  Patients on Valproic acid, and Felbamate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2002</study_first_submitted>
  <study_first_submitted_qc>May 2, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2002</study_first_posted>
  <last_update_submitted>March 15, 2011</last_update_submitted>
  <last_update_submitted_qc>March 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Siyu Liu, Vice President, North American IR&amp;D and Head of Global Clinical Operations</name_title>
    <organization>Teva Branded Pharmaceutical Products R&amp;D, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

